Overactive bladder in the elderly: A guide to pharmacological management

Drugs and Aging

Volumn 22, Issue 12, 2005, Pages 1013-1028

  Staskin, David R ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450 INHIBITOR; DARIFENACIN; DESMOPRESSIN; ESTROGEN; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

BEHAVIOR THERAPY; BLURRED VISION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL EXAMINATION; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PENETRATION; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRY SKIN; DYSPEPSIA; ERYTHEMA; HEARTBURN; HUMAN; HYDROPHOBICITY; LIPOPHILICITY; NOCTURIA; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PRURITUS; QUALITY OF LIFE; REVIEW; SKIN MANIFESTATION; SLEEP DISORDER; SYMPTOMATOLOGY; URINALYSIS; VAGINA ATROPHY; XEROSTOMIA;

AGED; BEHAVIOR THERAPY; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MUSCARINIC ANTAGONISTS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; URINARY INCONTINENCE;

EID: 29244484230     PISSN: 1170229X     EISSN: 1170229X     Source Type: Journal    
DOI: 10.2165/00002512-200522120-00003     Document Type: Review

References (80)

1. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36
2. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-Committee of the International Continence Society. Urology 2003; 61: 37-49
3. Malone-Lee J, Henshaw DJ, Cummings K. Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response. BJU Int 2003; 92: 415-7
4. Araki I, Zakoji H, Komuro M, et al. Lower urinary tract symptoms in men and women without underlying disease causing micturition disorder: a cross-sectional study assessing the natural history of bladder function. J Urol 2003; 170: 1901-4
5. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they man-aged? A population-based prevalence study. BJU Int 2001; 87: 760-6
6. Wilson L, Brown JS, Shin GP, et al. Annual direct cost of urinary incontinence. Obstet Gynecol 2001; 98: 398-406
7. Wagg A, Cohen M. Medical therapy for the overactive bladder in the elderly. Age Ageing 2002; 31: 241-6
8. Brocklehurst J. Urinary infection in old age. Nurs Elder 1990; 2: 17-8
9. Liberman JN, Hunt TL, Stewart WF, et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a US community-based survey. Urology 2001; 57: 1044-50
10. Brown JS, Subak LL, Gras J, et al. Urge incontinence: the patients' perspective. J Womens Health 1998; 7: 1263-9
11. Brown JS, Vittinghoff E, Wyman JF, et al. Urinary incontinence: does it increase risk of falls and fractures? J Am Geriatr Soc 2000; 48: 721-5
12. Thom DH, Haan MN, Van Den Eeden SK. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Ageing 1997; 26: 367-74
13. Resnick NM, Yalla SV. Aging and its effect on the bladder. Semin Urol 1987; 5: 82-6
14. Wagg A, Malone-Lee J. The management of urinary incontinence in the elderly. Br J Urol 1998; 82 Suppl. 1: 11-7
15. Wyndaele JJ, Van Meel TD, De Wachter S. Detrusor overactivity: does it represent a difference if patients feel the involuntary contractions? J Urol 2004; 172: 1915-8
16. Van Arsdalen K, Wein AJ. Physiology of micturition and continence. In: Krane RJ, Siroky M, editors. Clinical neurology. New York: Little Brown, 1991: 25-82
17. De Groat WC. A neurological basis for the overactive bladder. Urology 1997; 50 Suppl. 6A: 36-52
18. Andersson KE. Bladder activation: afferent mechanisms. Urology 2002; 59 Suppl. 5A: 43-50
19. 2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Am J Physiol Regul Intergr Comp Physiol 2004; 286: R874-80
20. Brading AF. A myogenic basis for the overactive bladder. Urology 2002; 60 Suppl. 5A: 57-67
21. Elbadawi A, Yalla SA, Resnick NM. Structural basis of geriatric voiding dysfunction: III. Detrusor overactivity. J Urol 1993; 150: 1668-80
22. Coolsaet BL, van Duyl WA, van Os-Bossagh P, et al. New concepts in relation to urge and detrusor activity. Neurourol Urodyn 1993; 12: 463-71
23. Cardozo L, Robinson D. Special considerations in premenopausal and postmenopausal women with symptoms of overactive bladder. Urology 2002; 60 Suppl. 5A: 64-71
24. Resnick NM. Geriatric incontinence. Urol Clin North Am 1996; 23: 55-74
25. Ouslander JG. Management of overactive bladder. N Engl J Med 2004; 350: 786-99
26. Gormley EA, Griffiths DJ, McCracken PN, et al. Polypharmacy and its effects on urinary incontinence in a geriatric population. Br J Urol 1993; 71: 265-9
27. Barry MJ, Fowler Jr FJ, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia: the Measurement Committee of the American Urological Association. J Urol 1992; 148 (5): 1549-57
28. Cardozo L, Coyne KS, Versi E. Validation of the urgency perception scale. BJU Int 2005; 95: 591-6
29. Matza LS, Thompson CL, Krasnow J, et al. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourol Urodyn 2005; 24: 215-25
30. National Kidney and Urologic Diseases Information Clearing-house. Kidney and urologic diseases [online]. Available from URL: http://kidney.niddk.nih.gov/ kudisease/pubs/diary/ [Accessed 2005 Oct 2]
31. Burgio KL, Locher JL, Goode PS, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized, controlled trial. JAMA 1998; 280: 1995-2000
32. Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc 2000; 48: 370-4
33. Szonyi G, Collas DM, Ding YY, et al. Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age Ageing 1995; 24: 287-91
34. Ouslander JG, Shih YT, Malone-Lee J, et al. Am J Manag Care 2002; 6 Suppl. 11: S559-606
35. Goode PS, Burgio KL, Locher JL, et al. Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women. J Am Geriatr Soc 2002; 50: 808-16
36. Siddiqui MA, Perry CM, Scott LJ. Oxybutynin extended-release: a review of its use in the management of overactive bladder. Drugs 2004; 64: 885-912
37. Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002; 168: 580-6
38. Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003; 62: 237-42
39. Malone-Lee J, Shaffu B, Anand C, et al. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol 2001; 165: 1452-6
40. Malone-Lee JG, Walsh JB, Maugourd M, et al. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001; 49: 700-5
41. Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 2002; 50: 799-807
42. Foote J, Glavind K, Kralidis G, et al. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol 2005; 48: 471-7
43. Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind, placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004; 93: 303-10
44. Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172: 1919-24
45. Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004; 171: 2311-5
46. Rudy D, Cline K, Harris R, et al. A multicenter, phase III trial studying trospium chloride in patients with overactive bladder, Urology. In press
47. Rovner ES. Trospium chloride in the management of overactive bladder. Drugs 2004; 64: 2433-46
48. Andersson KE, Yoshida M. Antimuscarinics and the overactive detrusor: which is the main mechanism of action? Eur Urol 2003; 43: 1-5
49. Clemett D, Jarvis B. Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging 2001; 18: 277-304
50. Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003; 78: 687-95
51. Gleason DG, Susset J, White C, et al. Evaluation of a new once daily formulation of oxybutynin for the treatment of urinary urge incontinence. Urology 1999; 54: 420-3
52. 3 muscarinic selective receptor for the treatment of overactive bladder. Expert Opin Investig Drugs 2004; 13: 1493-500
53. Chapple CR. Darifenacin is well tolerated and provides significant improvement in the symptoms of overactive bladder: a pooled analysis of phase III studies [abstract no.487]. J Urol 2004; 171 Suppl.: 130
54. Enablex® prescribing information. East Hanover (NJ): Novartis Pharmaceuticals Inc., 2004 Dec
55. Gittelman M, Klimberg I, Fincer R, et al. Two randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multicenter studies to assess the efficacy and safety of daily oral administration of 10mg YM905 versus placebo in male and female subjects with overactive bladder [abstract no. DP43]. J Urol 2003; 169 Suppl.: 349
56. VESIcare® prescribing information. Paramus (NJ): Astellas Pharma US Inc. and GlaxoSmithKline, 2005 Mar
57. Madersbacher H, Jahnig J, Rettig K. Irritable bladder symptoms and urge incontinence: effective therapy with Spasmo-Lyt coated tablets. Der Allgemeinarzt 1995; 4: 501-3
58. Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003; 20: 392-9
59. Mulsant BH, Pollock BG, Kirschner M, et al. Serum anticholinergic activity in a community-based sample of older adults. Arch Gen Psychiatry 2003; 60: 198-203
60. Tune L, Carr S, Hoag E, et al. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry 1992; 149: 1393-4
61. Womack KB, Heilman MK. Tolterodine and memory: dry but forgetful. Arch Neurol 2003; 60: 771-3
62. Katz IR, Sands LP, Bilker W, et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998; 46: 8-13
63. Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000; 55 Suppl. 5A: 33-46
64. Malavaud B, Bagheri H, Senard JM, et al. Visual hallucinations at the onset of tolterodine treatment in a patient with a highlevel spinal cord injury. BJU Int 1999; 84: 1109
65. Tsao JW, Heilman KM. Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med 2003; 349: 2274-5
66. Williams SG, Staudenmeier J. Hallucinations with tolterodine. Psychiatr Serv 2004; 55: 1318-9
67. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 2005; 173: 493-8
68. Jonkman JH, Westenberg HG, Rijntjes NV, et al. Whole body distribution of the quaternary ammonium compound thiazinamium (N-methylpromethazine) and promethazine in monkey and mice. Arzneimittelforschung 1983; 33: 223-8
69. Doroshyenko O, Jetter A, Odenthal KP, et al. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet 2005; 44: 701-20
70. Pietzko A, Dimpfel W, Schwantes U, et al. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 1994; 47: 337-43
71. Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride and oxybutynin on the central nervous system. J Clin Pharmacol 2001; 41: 636-44
72. Diefenbach K, Arnold G, Wollny A, et al. Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged ≥50 years. BJU Int 2005; 95: 346-9
73. Staskin DR, Harnett MD. Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Curr Sci 2004; 5: 423-6
74. Blennow K, Fredman P, Wallin A, et al. Protein analysis in cerebrospinal fluid: II. Reference values derived from healthy individuals 18-88 years of age. Eur Neurol 1993; 33: 129-33
75. Kleine TO, Hackler R, Zofel P. Age-related alterations of the blood-brain-barrier (bbb) permeability to protein molecules of different size. Z Gerontol 1993; 26: 256-9
76. Mooradian AD. Effect of aging on the blood-brain barrier. Neurobiol Aging 1988; 9: 31-9
77. Guay DRP. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet 2003; 42: 1243-85
78. Detrol® LA prescribing information. New York: Pharmacia and Upjohn Company, 2004 Apr [online]. Available from URL: http://www.detrolla.com/files/ DetrolLA.pdf [Accessed 2005 Nov 15]
79. Ditropan XL® prescribing information. Paritan (NJ): Ortho-McNeil Pharmaceutical Inc., 2003 Jun [online]. Available from URL: http://www. orthomcneil.com/products/pi/pdfs/ditropanxl.pdf [Accessed 2005 Nov 15]
80. Doroshyenko O, Jetter A, Odenthal KP, et al. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet 2005; 44: 701-20